Adiponectin gene expression in human primary adipocyte culture treated with uremic serum

End-stage renal disease (ESRD) is accompanied by an increased rate of morbidity and mortality due to cardiovascular disease (CVD). Although renal replacement therapy is required at this stage, it is associated with additional complications such as inflammation and dyslipidemia. It has been suggested...

Full description

Bibliographic Details
Main Authors: Sultan Alouffi, Matthew Howse, Ajay Sharma, Lakshminarayan Ranganath
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2015-01-01
Series:Saudi Journal of Kidney Diseases and Transplantation
Online Access:http://www.sjkdt.org/article.asp?issn=1319-2442;year=2015;volume=26;issue=6;spage=1190;epage=1198;aulast=Alouffi
_version_ 1811194641456824320
author Sultan Alouffi
Matthew Howse
Ajay Sharma
Lakshminarayan Ranganath
author_facet Sultan Alouffi
Matthew Howse
Ajay Sharma
Lakshminarayan Ranganath
author_sort Sultan Alouffi
collection DOAJ
description End-stage renal disease (ESRD) is accompanied by an increased rate of morbidity and mortality due to cardiovascular disease (CVD). Although renal replacement therapy is required at this stage, it is associated with additional complications such as inflammation and dyslipidemia. It has been suggested that adiponectin has anti-inflammatory properties. We studied the potential role of uremic mileu on the adiponectin expression in human primary adipocyte culture. A cohort of 18 patients with ESRD (hemo-and peritoneal dialysis) and nine healthy controls were analyzed in a prospective cross-sectional study. Single blood samples were taken pre-and post-hemodialysis and in peritoneal dialysis patients. Serum concentrations of total adiponectin (7.95 ± 1.44 μg/mL; 6.73 ± 1.2 μg/mL; 13.7 ± 3.04 μg/mL, respectively) and high molecular weight adiponectin (3.03 ± 1.95 μg/mL; 3.57 ± 2.44 14 μg/mL; 8.02 ± 5 μg/mL respectively) were measured. Other biochemical parameters (cholesterol, low-density lipoprotein cholesterol and triglycerides) were assessed in all groups of patients. Adiponectin gene expression was determined using real-time polymerase chain reaction, and was found to be lower in ESRD patients compared with healthy controls with low dose but not with high-dose treatments. Serum concentrations of total adiponectin and high molecular weight adiponectin were significantly higher in the ESRD versus control group. These results provide an initial insight into understanding the putative role of adipose tissue in contributing to the association of CVD risk in patients with chronic kidney disease.
first_indexed 2024-04-12T00:30:10Z
format Article
id doaj.art-acb5dcc3d05e4e32b765fb72db61828b
institution Directory Open Access Journal
issn 1319-2442
language English
last_indexed 2024-04-12T00:30:10Z
publishDate 2015-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Saudi Journal of Kidney Diseases and Transplantation
spelling doaj.art-acb5dcc3d05e4e32b765fb72db61828b2022-12-22T03:55:23ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422015-01-012661190119810.4103/1319-2442.168612Adiponectin gene expression in human primary adipocyte culture treated with uremic serumSultan AlouffiMatthew HowseAjay SharmaLakshminarayan RanganathEnd-stage renal disease (ESRD) is accompanied by an increased rate of morbidity and mortality due to cardiovascular disease (CVD). Although renal replacement therapy is required at this stage, it is associated with additional complications such as inflammation and dyslipidemia. It has been suggested that adiponectin has anti-inflammatory properties. We studied the potential role of uremic mileu on the adiponectin expression in human primary adipocyte culture. A cohort of 18 patients with ESRD (hemo-and peritoneal dialysis) and nine healthy controls were analyzed in a prospective cross-sectional study. Single blood samples were taken pre-and post-hemodialysis and in peritoneal dialysis patients. Serum concentrations of total adiponectin (7.95 ± 1.44 μg/mL; 6.73 ± 1.2 μg/mL; 13.7 ± 3.04 μg/mL, respectively) and high molecular weight adiponectin (3.03 ± 1.95 μg/mL; 3.57 ± 2.44 14 μg/mL; 8.02 ± 5 μg/mL respectively) were measured. Other biochemical parameters (cholesterol, low-density lipoprotein cholesterol and triglycerides) were assessed in all groups of patients. Adiponectin gene expression was determined using real-time polymerase chain reaction, and was found to be lower in ESRD patients compared with healthy controls with low dose but not with high-dose treatments. Serum concentrations of total adiponectin and high molecular weight adiponectin were significantly higher in the ESRD versus control group. These results provide an initial insight into understanding the putative role of adipose tissue in contributing to the association of CVD risk in patients with chronic kidney disease.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2015;volume=26;issue=6;spage=1190;epage=1198;aulast=Alouffi
spellingShingle Sultan Alouffi
Matthew Howse
Ajay Sharma
Lakshminarayan Ranganath
Adiponectin gene expression in human primary adipocyte culture treated with uremic serum
Saudi Journal of Kidney Diseases and Transplantation
title Adiponectin gene expression in human primary adipocyte culture treated with uremic serum
title_full Adiponectin gene expression in human primary adipocyte culture treated with uremic serum
title_fullStr Adiponectin gene expression in human primary adipocyte culture treated with uremic serum
title_full_unstemmed Adiponectin gene expression in human primary adipocyte culture treated with uremic serum
title_short Adiponectin gene expression in human primary adipocyte culture treated with uremic serum
title_sort adiponectin gene expression in human primary adipocyte culture treated with uremic serum
url http://www.sjkdt.org/article.asp?issn=1319-2442;year=2015;volume=26;issue=6;spage=1190;epage=1198;aulast=Alouffi
work_keys_str_mv AT sultanalouffi adiponectingeneexpressioninhumanprimaryadipocyteculturetreatedwithuremicserum
AT matthewhowse adiponectingeneexpressioninhumanprimaryadipocyteculturetreatedwithuremicserum
AT ajaysharma adiponectingeneexpressioninhumanprimaryadipocyteculturetreatedwithuremicserum
AT lakshminarayanranganath adiponectingeneexpressioninhumanprimaryadipocyteculturetreatedwithuremicserum